This study evaluated the safety and efficacy of the immunostimulatory agent OM-85 BV in 112 male car-factory workers who were highly susceptible to acute respiratory tract infections (ARTIs), each having experienced ≥ 4 ARTIs during 1999. From January to March 2000, each worker received one capsule of OM-85 BV (7 mg) per day for 10 consecutive days each month. The patients were followed for a further 9 months. Mean number of ARTIs decreased from 8.2 ± 2.1 per worker in 1999 to 5.3 ± 2.9 in 2000; i.e. a difference of -2.9 (95% confidence intervals, -3.5 to -2.4). Similar effects were observed in men who had different job roles, and no adverse events were reported during drug administration. We concluded that OM-85 BV appears to be safe and effective in reducing the incidence of ARTIs in susceptible workers, although further double-blind, placebo-controlled clinical trials are required.
Introduction
Acute respiratory tract infections (ARTIs) are among the most frequent reasons for seeking ambulatory care in the USA 1,2 and the majority of antibiotic prescriptions are written to treat these infections. 3, 4 The World Health
Organization calls ARTIs 'the forgotten pandemic', 5 and their cost is an important component in global health expenditure. 5 -7 The role of the immunostimulant OM-85 BV (Broncho-Vaxom ® , OM PHARMA, Geneva, Switzerland, marketed in Mexico by Química Knoll de México) in the prevention of ARTIs has been studied. 8 -13 OM-85 BV is the product of alkaline proteolysis of lysates obtained 15 and ARTIs in children living in an orphanage who were over-exposed to pathogens. 16 In adults suffering from exacerbations of chronic obstructive pulmonary disease, OM-85 BV reduced the number and duration of hospitalizations. 12 An open trial of OM-85 BV, conducted by the Ford Motor Company in Argentina, showed a fall in the number of infections OM-85 BV for ARTIs reported when OM-85 BV was given to 65 workers with a history of recurrent ARTIs. The number of infections dropped from 138 (mean per worker ± SD, 2.1 ± 1.3) to 41 (0.6 ± 0.8) over the winter period in consecutive years, and related sickness absences (in days) fell from 131 (2.0 ± 3.2) to 31 (0.5 ± 1.5). 17 The present study evaluated the safety and efficacy of OM-85 BV in the prevention of recurrent ARTIs in a larger group of car manufacturing workers over a 12-month period.
Patients and methods
An open-label, prospective trial was conducted in workers of the Ford Motor Company in Cuautitlan, Mexico. The selection criteria were as follows: each individual had experienced ≥ 4 ARTIs during 1999 (information was obtained from 1999 occupational health records); no anatomical alterations of the respiratory tract were observed on physical examination; no patient had tuberculosis or cystic fibrosis, autoimmune diseases, liver failure or kidney failure; and no patient had received treatment with corticosteroids, immunosuppressants, immunostimulants, γ-globulins or anti-convulsive agents in the 6 months prior to starting the trial.
Patients were excluded from the trial if they withdrew informed consent, experienced serious adverse events or serious concomitant disease, or had protocol violations.
Informed consent was obtained for each participant. The local medical committee approved the protocol and case-report form, and the trial was conducted according to Mexican regulations and the Helsinki Declaration of 1975 (1983 revision).
The patients took one 7-mg capsule of OM-85 BV orally per day for 10 consecutive days each month, for a period of 3 consecutive months (January -March 2000). Empty blister packs were kept to control compliance. Patients were followed for a further 9 consecutive months, giving a trial duration of 12 months. An ARTI was defined as the presence of at least one of the following signs: rhinorrhoea, sore throat or cough for ≥ 48 h. Patients were assessed every time they experienced respiratory symptoms and all ARTIs were followed up until clinical symptoms resolved. Two infections were counted as such only when a patient was without symptoms for ≥ 72 h between the end of one symptomatic episode and the beginning of the next. Adverse events were registered in clinical files and in the adversereport form as they occurred, and reported monthly in the case-report form.
The number of ARTIs and days off work due to ARTIs during 1999 and 2000 were compared by paired Student's t-test and the Wilcoxon test, using SPSS statistics software (SPSS Inc., Chicago, IL, USA). P-values ≤ 0.05 were considered statistically significant.
Results
In total, 112 male car manufacturing workers were included in the trial, with a mean age of 37.9 ± 8.0 years and weight of 78.5 ± 14.6 kg. Thirty-eight of these were smokers and there were no cases of chronic obstructive pulmonary disease. The specific job roles of the workers are shown in Table 1 .
The mean number of ARTIs was 8.2 ± 2.1 per worker during 1999, decreasing to 5.3 ± 2.9 by 2000 (P < 0.001, Student's t-test), which corresponds to a -2.9 incidence reduction (95% confidence interval [CI], -3.5 to -2.4).
Smokers had higher incidences of ARTIs in both years, and we observed less of a reduction in infection rates between smokers and non-smokers across the study periods: smokers experienced 8. 
Discussion
Acute respiratory tract infections are difficult to control. It is hard to avoid transmitting these infections, and specific immunization for all causative agents is impractical. Although ARTIs are apparently trivial, they are a burden on society. 5 In this trial, we explored the protective effects of OM-85 BV in the prevention of recurrent ARTIs in car manufacturing workers. We found, in a 12-month period, a 35% reduction in the incidence of ARTIs but no difference in the amount of sick leave taken because of ARTIs.
The percentage of disease reduction observed was not as dramatic as the -71% reduction in incidence (and considerable reduction in sick leave due to ARTIs) described by De Marco et al. 17 in another Number of ARTIs MA Carmona-Ramírez, V Alvárez-Gómez, A Berber OM-85 BV for ARTIs study over a similar winter period. The differences in percentage of disease reduction may be ascribed to differences in patient selection. The present trial included workers who reported higher rates of ARTIs, whereas administration of the immunostimulant agent and follow-up periods differed between the studies. 17 Differences in sick leave reported between our study and that of De Marco et al. 17 may be due to the very low number of sick days taken by the Mexican workers. A protective effect of OM-85 BV was detected in smokers and non-smokers in the present study, and was similar for men with different job roles.
A recent review claims that the placebo effect is very small and may be dismissed, 18 but we believe that the placebo effect and confounders such as weather conditions are worthy of consideration. While our findings indicate important benefits of OM-85 BV in the prevention of ARTIs in occupational medicine, and confirm the results of previous trials performed in other patient groups, the true value of OM-85 BV in the prevention of ARTIs in occupational medicine can only be assessed by large, double-blind, placebocontrolled clinical trials.
